"MedAustron ist ein österreichweit einzigartiges Krebsbehandlungs- und Forschungszentrum. Patientinnen und Patienten werden bei MedAustron mit der Ionentherapie behandelt, einer evolutionären Form der Strahlentherapie zur Krebsbehandlung. Dabei kommen geladene Teilchen – Protonen oder Kohlenstoffionen – zum Einsatz. Die besonderen Eigenschaften dieser Teilchen machen die Ionentherapie optimal zur Behandlung von Tumoren in der Nähe von strahlungsempfindlichen Organen."

During the past decade, EBG MedAustron GmbH conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "EBG MedAustron GmbH" #1 collaborator was "Landesklinkum Wiener Neustadt" with 2 trials as a collaborator, "CW-Research & Management GmbH" with 1 trials as a collaborator, "Klinik Ottakring" with 1 trials as a collaborator and "Medical University of Vienna" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "EBG MedAustron GmbH" are "Cancer" (1 trials), "Intermediate Risk Prostate Cancer" (1 trials), "Ion Beam Radiation Therapy for Tumor Patients" (1 trials), "Low Risk Prostate Cancer" (1 trials) and "Pancreas Cancer" (1 trials). Many other conditions were trialed in "EBG MedAustron GmbH" in a lesser frequency.

Most popular intervention types in "EBG MedAustron GmbH" are "Radiation" (5 trials), "Diagnostic Test" (2 trials), "Drug" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)" (2 trials), "Blood sampling" (2 trials), "Computertomography" (2 trials), "Magnetic resonance imaging" (2 trials) and "Capecitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "EBG MedAustron GmbH" are 4 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "EBG MedAustron GmbH". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in EBG MedAustron GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in EBG MedAustron GmbH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".